Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sin Gon | - |
dc.contributor.author | Kim, Kyoung Jin | - |
dc.contributor.author | Yoon, Kun Ho | - |
dc.contributor.author | Chun, Sung Wan | - |
dc.contributor.author | Park, Kyong Soo | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.contributor.author | Lim, Soo | - |
dc.contributor.author | Mok, Ji-Oh | - |
dc.contributor.author | Lee, Hyoung Woo | - |
dc.contributor.author | Seo, Ji A. | - |
dc.contributor.author | Cha, Bong-Soo | - |
dc.contributor.author | Kim, Mi Kyung | - |
dc.contributor.author | Shon, Ho Sang | - |
dc.contributor.author | Choi, Dong Seop | - |
dc.contributor.author | Kim, Doo Man | - |
dc.date.accessioned | 2021-08-11T08:32:45Z | - |
dc.date.available | 2021-08-11T08:32:45Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.issn | 1463-1326 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2455 | - |
dc.description.abstract | We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were -0.79% and -0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, -0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (-11.9% vs. -4.8%;P < .0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeks | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/dom.14085 | - |
dc.identifier.scopusid | 2-s2.0-85086589945 | - |
dc.identifier.wosid | 000540754100001 | - |
dc.identifier.bibliographicCitation | Diabetes, Obesity and Metabolism, v.22, no.10, pp 1869 - 1873 | - |
dc.citation.title | Diabetes, Obesity and Metabolism | - |
dc.citation.volume | 22 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1869 | - |
dc.citation.endPage | 1873 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | GAMMA AGONIST | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PIOGLITAZONE | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | lobeglitazone | - |
dc.subject.keywordAuthor | randomized trial | - |
dc.subject.keywordAuthor | thiazolidinediones | - |
dc.subject.keywordAuthor | type 2 diabetes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.